Preface

In 2022, we are in our 22nd year for Current Molecular Medicine. Based on our excellent progress and the concomitant reputation gained during these years, we are happy to announce that the journal's impact factor increased to 2.22. To generate higher impact for the work of the authors by submitting to our high-quality journal with wide readership and rapid processing times, CMM will provide a smooth publishing experience and help to achieve maximum scientific impact.

First of all, I would like to express my sincere gratitude for the time and expert efforts of all external peer-reviewers to provide their recommendations regarding the quality of the submitted articles as well as the corresponding authors who responded to the concerns of the reviewers in bringing their studies to publication. With our very thorough review process and the high quality manuscripts, the editorial board expect further increase in the impact factor of the journal in the upcoming year. Similar to as before, in 2022, we will publish comprehensive and critical reviews of molecular medicinal interests as well as original research articles on special hot topics.

The first issue of Current Molecular Medicine in 2022 contains seven high quality articles (5 review papers and 2 research articles) covering a broad range of molecular medicine. The issue starts with a mini-review about leukemia infection diagnosis. It is followed by four regular review articles, the first focusing on epigenetic effects of environmental factors causing / inhibiting cancers; the second about the state of art and future prospects of molecular and metabolic imaging of castration-resistant prostate cancer; the third revealing the roles of mitochondrial dysfunction and reactive oxygen species in aging and the fourth is a very timely overview about SARS-CoV-2 proteins focusing on their usefulness as targets for covid-19 drugs and vaccines. The reviews are followed by two original research papers, including a study on the impact of cell-free plasma DNA on metastatic and non-metastatic prostate cancer. The closing research article is enlightening the polymorphisms of the NF-kB1 intronic region as a risk factor for head and neck cancer in HPV-infected population from Pakistan. I do believe that this collection of papers represents a great kick-off for the upcoming year.

At the beginning of 2022, I would like to express my sincere gratitude to the Editorial Board Members and the Editorial Team of Bentham Science Publishers for their assistance and continuous support to the progress of the journal. I also greatly appreciate the help of my colleague Dr László Hajba during the editorial duties. We look forward to the continued support of our readers and contributing authors with the belief that 2022 will be another fruitful year for the journal.

With this, I would like to wish you all a Happy and Healthy New Year.

András Guttman
Editor-in-Chief
Current Molecular Medicine
Horváth Csaba Memorial Laboratory of Bioseparation Sciences, University of Debrecen Debrecen, Hungary
E-mail: andrasguttman@gmail.com